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The recent epidemic of Zika virus (ZIKV) in the Americas and its association with fetal and neurological
complications has shown the need to develop a treatment. Repurposing of drugs that are already FDA
approved or in clinical development may shorten drug development timelines in case of emerging viral
diseases like ZIKV. Initial studies have shown conﬂicting results when testing sofosbuvir developed for
treatment of infections with another Flaviviridae virus, hepatitis C virus. We hypothesized that the
conﬂicting results could be explained by differences in intracellular processing of the compound. We
assessed the antiviral activity of sofosbuvir and mericitabine against ZIKV using Vero, A549, and Huh7
cells and measured the level of the active sofosbuvir metabolite by mass spectrometry. Mericitabine did
not show activity, while sofosbuvir inhibited ZIKV with an IC50 of ~4 mM, but only in Huh7 cells. This
correlated with differences in intracellular concentration of the active triphosphate metabolite of
sofosbuvir, GS-461203 or 007-TP, which was 11e342 times higher in Huh7 cells compared to Vero and
A549 cells. These results show that a careful selection of cell system for repurposing trials of prodrugs is
needed for evaluation of antiviral activity. Furthermore, the intracellular levels of 007-TP in tissues and
cell types that support ZIKV replication in vivo should be determined to further investigate the potential
of sofosbuvir as anti-ZIKV compound.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Zika virus (ZIKV) is an arthropod-borne ﬂavivirus and belongs to
the family of Flaviviridae. It has gained global attention due to the
recent emergence in the Americas, and the newly observed asso-
ciation with fetal and neurological complications (Lazear et al.,
2016). Given this widespread emergence and the concern about
neurological complications, ways to reduce the impact of infection
are urgently needed. However, neither vaccines nor drugs are
available, and their development requires a lengthy process before
being available for use (Ekins et al., 2016). The repurposing of drugs,
which are already FDA-approved or in clinical development, may
shorten drug development timelines in case of emerging viral
diseases like ZIKV (Mumtaz et al., 2016). For ZIKV, large libraries of
FDA-approved drugs have been screened, including direct-acting
antivirals of hepatitis C virus (HCV) which also belongs to theent of Viroscience, Unit of
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r B.V. This is an open access articleFlaviviridae family (Zmurko et al., 2016; Gane et al., 2013; Eyer et al.,
2016; van der Eijk et al., 2016). Conﬂicting results were recently
reported on the antiviral activity of the anti-HCV drug sofosbuvir
when testing its effect on ZIKV replication: no anti-ZIKV activity
was reported using Vero cells while others reported activity using
Huh7, BHK-21, SH-Sy5y cells and neuronal stem cells (Eyer et al.,
2016; Sacramento et al., 2016; Bullard-Feibelman et al., 2016).
Though in vitro susceptibility testing of drugs against emerging
viruses may seem straightforward, it should be carried out with
certain considerations. Cell culture systems should be chosen with
detailed knowledge about the pharmacodynamics and pharmaco-
kinetic properties of the drugs along with information of active
components and target cells. We hypothesized that these con-
ﬂicting results could be explained by differences in the intracellular
concentration of the active triphosphate form of sofosbuvir, GS-
461203 or 007-TP, which were not provided in the publications.
We studied the antiviral activity of the anti-HCV compounds
sofosbuvir andmericitabine against ZIKV, because it was previously
shown that these two compounds inhibited replication of the
closely related dengue virus using Huh7 cells (Bluemling et al.,under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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against two ZIKV strains belonging to the Asian lineage (H/PF/2013
[ZIKVASFP13] and ZIKVNL00013 [ZIKVASSur16]) (van der Eijk et al.,
2016) were tested using A549 cells (human pneumocyte type II
carcinoma cells), Vero cells (African green monkey kidney epithe-
lial cells) and Huh7 cells (human hepatocellular carcinoma cells).
Virus isolates are available through the European virus archive with
EVAg accession numbers 001V-EVA1545 and 011V-01621, respec-
tively (https://www.european-virus-archive.com). Huh7 cells were
included in view of the dengue virus studies (Bluemling et al.,
2014), Vero cells because they are routinely used for ZIKV isola-
tion, and A549 cells because these cells strongly expresses car-
boxylesterase 1 (CES1) which is needed for activation of sofosbuvir
(Hosokawa, 2008; Murakami et al., 2010). We measured the
intracellular concentration of 007-TP to further investigate the cell-
line dependent antiviral activity of sofosbuvir against ZIKV.
Cell viability assays (Cell Titer 96® Aqueous One Solution Reagent,
Promega) with sofosbuvir and mericitabine showed 50% cell cyto-
toxicity concentrations (CC50) of >100 mM for both drugs. Anti-ZIKV
activity was tested by plaque reduction assay (PRA). In PRA, all
three cell lines were challenged with ~0.001 MOI of ZIKV and
incubated with 0.09 mMe50 mM (2-fold serial dilutions) of sofos-
buvir and mericitabine for 3 days (37 C, 5% CO2). After 3 days of
incubation, plaques were visualized with True Blue staining using
mouse monoclonal antibody to ZIKV NS1 protein (Aalto Bio Re-
agents, USA) as primary antibody and HRP-labeled goat anti-mouse
antibody as secondary antibody. Mericitabine did not show any
inhibition of ZIKV (IC50 > 50 mM). Sofosbuvir inhibited ZIKVASFP13
and ZIKVASSur16 replication in Huh7 cells with IC50 values around
4 mM, but not in Vero and A549 cells (Table 1). To validate the
ﬁndings from the plaque reduction assays, we analyzed the dose-
dependent inhibition of ZIKV replication by both drugs using
cytopathic effect (CPE) reduction assays and virus yield reduction
assays. Using a multiplicity of infection of 0.1, we again observed an
IC50 of about 4 mM using the Huh7 cells, while no inhibition was
observed with Vero cells. Supernatants from CPE reduction assay
were titrated to quantify the new progeny virus titers, showing that
ZIKV replication was inhibited 95% by 25 mM and 50 mM sofos-
buvir using Huh7 cells, while no reduction in infectious titers was
observed in Vero cells. To further understand the cell-line depen-
dent inhibition of ZIKV by sofosbuvir, the active triphosphate form,
007-TP, was measured in all the three cell lines. Each cell line was
treated with 5 mM and 50 mM of sofosbuvir and incubated for 48 h
(37 C, 5% CO2). After 2 days of incubation, supernatants were
removed and cell lysates were prepared for mass spectrometric
analysis as described previously (Rower et al., 2015). Intracellular
007-TP concentrations were 11 and 158 lower in A549 and Vero,Table 1
Summary of in vitro assays and IC 50 values.
Cell systems VERO Huh7
ZIKV strains ZIKVASFP13 ZIKVASSur16 ZIKVASFP13
Antivirals SB MB SB MB SB M
CC50 (mM) >100 >100 >100 >100 >100 >
PRA
(IC50 mM)
>50 >50 >50 >50 3.9 >
CPE
(IC50 mM)
>50 >50 >50 >50 4.0 >
In the cell viability assay, cell lines were incubated for three days with sofosbuvir and
VASFP13and ZIKVASSur16 and incubated with different concentrations of sofosbuvir and
days of incubation the overlay was aspirated and cells were ﬁxed with formalin for immu
were infected with 0.1 moi of ZIKVASFP13and ZIKVASSur16 and after three days cells were
CPE). For the virus yield reduction assay (see text), supernatants from the CPE reduction as
CPE as read-out. For all experiments medium with 10% FBS was used. PRA ¼ Plaque Redrespectively, than in Huh7 cells when incubated with 5 mM sofos-
buvir (see Table 2). The intracellular concentrations were 25 and
342 lower in A549 and Vero, respectively, compared to Huh7 cells
when incubated with 50 mM sofosbuvir.
Sofosbuvir is a phosphoramidate nucleotide analogue and the
metabolic pathway involves hydrolysis of the carboxyl ester moiety
by cathepsin A (CatA) or carboxylesterase 1 (CES1) and phosphor-
amidate cleavage by histidine triad nucleotide-binding protein 1
(HINT1) followed by phosphorylation by uridine monophosphate-
cytidine monophosphate kinase (UMP-CMP kinase) and nucleo-
side diphosphate kinase (NDPK) to its active metabolite 007-TP, a
uridine-triphosphate analogue which inhibits the viral RNA
dependent RNA polymerase (RdRp) (Serrano and Manns, 2012)
(Hurwitz and Schinazi, 2013). Mericitabine, a nucleoside analogue,
also inhibits the viral RdRp, but other enzymes are involved in the
metabolism to the active triphosphate form (Ma et al., 2007).
Bluemling et al. reported the inhibition of dengue virus, a virus
closely related to ZIKV, by mericitabine and sofosbuvir using Huh7
cells, but this is still unpublished work (Bluemling et al., 2014).
Mericitabine inhibits hepatitis C virus in Huh7 using a virus repli-
con system (Bassit et al., 2008). This implies that the active
triphosphate forms of both drugs are formed in Huh7 cells,
although these measurements were not included in these studies.
We did not observe any inhibition of ZIKV by mericitabine using
Huh7 cells, which suggests that the RdRp of ZIKV is not inhibited by
the active triphosphate form of mericitabine. In contrast, sofosbuvir
did inhibit the replication of ZIKV in Huh7 cells but not in Vero cells
and A549 cells, which correlated with the intracellular concentra-
tion of 007-TP. One explanation for the difference in intracellular
concentration could be that activation of sofosbuvir by cellular
enzymes in A549 cells and Vero cells is less efﬁcient than in Huh7
due to the absence of CES1 activity (Hosokawa, 2008). However,
CES1 enzymes are thought to be present in the A549 cell line, which
nevertheless metabolized sofosbuvir less well. However, the
expression of other enzymes that are involved in the metabolic
activation of sofosbuvir may be lower in A549 cells and Vero cells
compared to Huh7 cells. Currently there is no data available on the
comparative expression proﬁles of these enzymes in Huh7, A549
and Vero. Another possible explanation may be the overexpression
of drug efﬂux pumps, such as the multi-drug resistance ABC-
transporter, which might have cleared sofosbuvir and/or its me-
tabolites from Vero and A549 cell lines (Guo et al., 2014; Sung et al.,
2008). However, the role of drug efﬂux pumps still need further
investigation as other nucleoside analogues like NITD008 exhibit
antiviral activity against DENV and ZIKV in A549 and Vero cells
(Deng et al., 2016; Yin et al., 2009).
Our data shows that selection of cell lines to screen prodrugs forA549
ZIKVASSur16 ZIKVASFP13 ZIKVASSur16
B SB MB SB MB SB MB
100 >100 >100 >100 >100 >100 >100
50 4.0 >50 >50 >50 >50 >50
50 4.1 >50 e e e e
mericitabine. In PRA, all three cell lines were challenged with ~0.001 MOI of ZIK-
mericitabine for 3 days using 1.6% carboxyl methyl cellulose (CMC) overlay. After 3
no-histochemical staining to visualize the plaques. In CPE reduction assay cells, cells
scored for CPE using a scale from 0 to 4 (0 meaning no CPE and 4meaning 75%e100%
saywere titrated and incubated for 5 days to quantify new progeny virus titers using
uction assay. SB ¼ Sofosbuvir. MB ¼ Mericitabine.
Table 2
Measurement of intracellular active metabolite 007-TP by LC-MS/MS.
Sofosbuvir Conc. (mM) 007-TP (PMOL/10^6 Cells)
Huh-7 cells A549 cells Vero cells
5 416 (SD ¼ 13.5) 36.20 (SD ¼ 0.95) 2.63 (SD ¼ 0.05)
50 5174 (SD ¼ 158) 204 (SD ¼ 7.90) 15.11 (SD ¼ 0.28)
For all experiments medium with 10% FBS was used.
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give false negative results in compound screening studies (Eyer
et al., 2016). The average plasma Cmax in humans using a single
dose of 1200 mg sofosbuvir is nearly equivalent to the IC50 of 4 mM
that we found in the Huh7 liver cell line (Kirby et al., 2015). Thus,
using this dosage, sufﬁciently high plasma concentrations of
sofosbuvir may be reached to inhibit ZIKV in humans. It should
however be noted that sofosbuvir has been developed for treat-
ment of a hepatotropic virus, and is designed to facilitate the
intracellular penetration in liver tissue, whereas there is lack of
data on the uptake and intracellular activation of sofosbuvir in
other tissues. For this, understanding the cell tropism of (early)
ZIKV infection is important in order to select cell lines relevant for
drug repurposing screening. Bullard et al. reported an anti-ZIKV
EC50 of 1e5 mM for sofosbuvir using Huh7 cells and an EC50 of
32 mM using neuronal stem cells (Bullard-Feibelman et al., 2016).
The higher EC50 of sofosbuvir in neuronal stem cells may reﬂect the
lower CES1 activity in brain tissue compared to liver tissue (Satoh
et al., 2002). Thus, to further investigate the potential of sofosbu-
vir as anti-ZIKV compound, intracellular concentrations of the
active metabolite 007-TP in cell types and tissues known to support
ZIKV replication in vivo should be taken into account. Since
measuring 007-TP levels in various tissues is technically chal-
lenging, measuring expression levels of enzymes involved in the
metabolic activation of sofosbuvir in these cell types and tissues
may be a good alternative. Furthermore, given the high uptake of
sofosbuvir in liver tissue, further pursuing the activity of sofosbuvir
against other ﬂaviviruses, in particular those with liver tropism like
yellow fever virus, is warranted.
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